Anti-HER2 vaccines: new prospects for breast cancer therapy
Open Access
- 8 June 2010
- journal article
- review article
- Published by Springer Science and Business Media LLC in Cancer Immunology, Immunotherapy
- Vol. 59 (9), 1295-1312
- https://doi.org/10.1007/s00262-010-0869-2
Abstract
Each year, breast cancer accounts for more than 400,000 new cancer cases and more than 130,000 cancer deaths in Europe. Prognosis of nonmetastatic breast cancer patients is directly related to the extent of the disease, mainly nodal spreading and tumor size, and to the molecular profile, particularly HER2 over-expression. In patients with HER2-over-expressing tumors, different studies have shown cellular and/or humoral immune responses against HER2 associated with a lower tumor development at early stages of the disease. These findings have led to the hypothesis that the generation of an anti-HER2 immune response should protect patients from HER2-over-expressing tumor growth. Taken together with the clinical efficiency of trastuzumab-based anti-HER2 passive immunotherapy, these observations allowed to envisage various vaccine strategies against HER2. The induction of a stable and strong immunity by cancer vaccines is expected to lead to establishment of immune memory, thereby preventing tumor recurrence. However, an immunological tolerance against HER2 antigen exists representing a barrier to effective vaccination against this oncoprotein. As a consequence, the current challenge for vaccines is to find the best conditions to break this immunological tolerance. In this review, we will discuss the different anti-HER2 vaccine strategies currently developed; considering the strategies having reached the clinical phases as well as those still in preclinical development. The used antigen can be either composed of tumoral allogenic cells or autologous cells, or specific to HER2. It can be delivered by dendritic cells or in a DNA, peptidic or proteic form. Another area of research concerns the use of anti-idiotypic antibodies mimicking HER2.Keywords
This publication has 133 references indexed in Scilit:
- Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivoInternational Journal of Cancer, 2010
- Genetic Regulation of the Response to Her-2 DNA Vaccination in Human Her-2 Transgenic MiceCancer Research, 2008
- Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize in vivo and induce an antitumor immune responseProceedings of the National Academy of Sciences of the United States of America, 2008
- Randomized Phase 3 Trial of Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast CancerJNCI Journal of the National Cancer Institute, 2008
- Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patientsProceedings of the National Academy of Sciences of the United States of America, 2008
- Challenges and prospects of immunotherapy as cancer treatmentBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2007
- Tregs and rethinking cancer immunotherapyJCI Insight, 2007
- Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapyThe Journal of Experimental Medicine, 2006
- Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective studyBritish Journal of Cancer, 2006
- Structure of the extracellular region of HER2 alone and in complex with the Herceptin FabNature, 2003